Multi-omic Evaluation of Metabolic Alterations in Multiple Sclerosis Identifies Shifts in Aromatic Amino Acid Metabolism

Kathryn C. Fitzgerald, Matthew D. Smith, Elias S. Sotirchos, Michael D. Kornberg, Morgan Douglas, Bardia Nourbakhsh, Jennifer Graves, Ramandeep Rattan, Laila Poisson, Mirela Cerghet, Ellen M. Mowry, Emmanuelle Waubant, Shailendra Giri, Peter A. Calabresi, Pavan BhargavamedRxiv 2021 · DOI

Abstract

The circulating metabolome is a product of interactions between the genome, epigenome, exposome and microbiome. The metabolome may be altered in people with multiple sclerosis (MS); however, existing metabolomics studies were relatively small or characterized a limited number of metabolites. Herein, we performed a multi-site study profiling the circulating metabolome to obtain relative abundances for 269 metabolites in a large cohort of MS patients and healthy controls. After adjusting for batch effects and extensive quality control, we created an overall metabolic dysfunction score, defined apriori sets of metabolites using known metabolic pathways, and derived novel networks of correlated metabolites using a weighted correlation network analysis (WGCNA). We assessed whether metabolic dysfunction, individual metabolites, metabolic pathways or WGCNA-identified module scores differed between people with MS versus healthy controls (HC) after adjusting for age, sex and race using generalized estimating equations. In a subset of patients, information on disability status was also available. Similar models assessed the association between metabolites and metabolite sets with measures of disability. In people with MS, we identified striking abnormalities in a WGCNA-defined module enriched in aromatic amino acid (AAA) metabolites (FDR-adjusted p-value=2.77E-18) that are also strongly associated with disability (FDR-adjusted p-value for AAA module=1.01E-4). Consistent results were obtained using apriori-defined metabolite sets or in analyses of individual metabolites. The identified abnormalities likely relate to imbalances in gut microbial metabolism of AAAs resulting in reduced production of immunomodulatory metabolites and increased production of metabotoxins (indole acetate, phenylacetylglutamine, p-cresol sulfate, p-cresol glucuronide). Single cell RNA sequencing data analysis demonstrated altered AAA metabolism in CSF and blood derived monocyte cell populations, while treatment of human peripheral blood mononuclear cells with AAA-derived metabotoxins resulted in increased production of tumor necrosis factor-α. We identify novel metabolic alterations in people with MS potentially contributing to disease pathophysiology.

Introduction

Multiple Sclerosis (MS) is a complex neurodegenerative disease driven by an interplay of genetic and environmental factors. While current disease-modifying therapies (DMTs) primarily target the immune system, the underlying metabolic shifts driving disease progression remain poorly understood. The circulating metabolome—the collection of small molecules in the blood—reflects the interaction between the genome, diet, and the gut microbiome. This study provides a high-resolution map of the MS metabolome, identifying a systemic shift in aromatic amino acid (AAA) metabolism that correlates with clinical disability.

Methodology

The researchers employed a multi-site, multi-omic approach to profile the circulating metabolome of 756 individuals (954 blood samples) across three clinical sites: Johns Hopkins MS Center, the UCSF Pediatric MS Cohort, and the Accelerated Cure Project.

  • Metabolomics: Relative abundances of 269 metabolites were measured and adjusted for batch effects.
  • Network Analysis: Weighted Correlation Network Analysis (WGCNA) identified modules of co-regulated metabolites, while Prize-collecting Steiner Forest (PCSF) was used to map these onto biological pathways.
  • Single-Cell Integration: Findings were integrated with publicly available single-cell RNA sequencing (snRNA-seq) data from blood and cerebrospinal fluid (CSF) to observe metabolic gene expression in immune cells.
  • Functional Validation: In vitro experiments assessed the impact of specific "metabotoxins" on human peripheral blood mononuclear cells (PBMCs) to observe cytokine production.

Key Findings

The Aromatic Amino Acid (AAA) Shift

The most significant finding was a profound abnormality in a metabolite module enriched for AAAs (tryptophan, tyrosine, and phenylalanine). In healthy controls, these amino acids are typically processed via reductive pathways into immunomodulatory molecules like indolelactate. In MS patients, the balance shifts toward oxidative pathways, producing "metabotoxins" such as p-cresol sulfate, p-cresol glucuronide, and indole acetate. This shift was highly significant, with the WGCNA "pink" module showing a massive difference between MS and healthy controls (FDR-adjusted p = 2.77E-18).

Gut-Microbiome and Inflammation

Many of the identified metabolites are products of gut microbial metabolism. The study suggests that an altered gut microbiome in MS patients drives the production of these metabotoxins. Functional assays demonstrated that treating monocytes with indole acetate (IAA) led to a dose-dependent increase in the production of tumor necrosis factor-α (TNF-α), a key pro-inflammatory cytokine in MS pathophysiology.

Clinical Correlation with Disability

The metabolic signature was not merely a diagnostic marker but also a prognostic one. The AAA module score and the ratio of oxidative to reductive metabolites correlated strongly with the Expanded Disability Status Scale (EDSS) and measures of retinal neurodegeneration via Optical Coherence Tomography (OCT). Patients with higher levels of oxidative metabolites were more likely to require walking aids (p < 0.001 for several AAA ratios), suggesting these metabolic changes are linked to disease severity.

Discussion and Limitations

This study highlights a potential "metabolic tug-of-war" in MS, where the loss of protective metabolites and the gain of toxic ones contribute to neuroinflammation. However, the cross-sectional nature of the data limits the ability to determine causality—it remains unclear if these metabolic shifts cause MS progression or result from it. While sensitivity analyses were performed on untreated patients, the influence of various DMTs on the metabolome remains a factor. Furthermore, while the metabolites point to the gut, direct microbiome sequencing was not included in this specific study.

Future research should focus on longitudinal tracking of these metabolic signatures and interventional trials, such as dietary or probiotic strategies, to restore the balance of AAA metabolism and potentially slow disease progression.

Summary updated

Abstract

ABSTRACT The circulating metabolome is a product of interactions between the genome, epigenome, exposome and microbiome. The metabolome may be altered in people with multiple sclerosis (MS); however, existing metabolomics studies were relatively small or characterized a limited number of metabolites. Herein, we performed a multi-site study profiling the circulating metabolome to obtain relative abundances for 269 metabolites in a large cohort of MS patients and healthy controls. After adjusting for batch effects and extensive quality control, we created an overall metabolic dysfunction score, defined apriori sets of metabolites using known metabolic pathways, and derived novel networks of correlated metabolites using a weighted correlation network analysis (WGCNA). We assessed whether metabolic dysfunction, individual metabolites, metabolic pathways or WGCNA-identified module scores differed between people with MS versus healthy controls (HC) after adjusting for age, sex and race using generalized estimating equations (participants could provide multiple samples). In a subset of patients, information on disability status was also available. Similar models assessed the association between metabolites and metabolite sets with measures of disability. In people with MS, we identified striking abnormalities in a WGCNA-defined module enriched in aromatic amino acid (AAA) metabolites (FDR-adjusted p-value=2.77E-18) that are also strongly associated with disability (FDR-adjusted p-value for AAA module=1.01E-4). Consistent results were obtained using apriori-defined metabolite sets or in analyses of individual metabolites. The identified abnormalities likely relate to imbalances in gut microbial metabolism of AAAs resulting in reduced production of immunomodulatory metabolites and increased production of metabotoxins (indole acetate, phenylacetylglutamine, p-cresol sulfate, p-cresol glucuronide). Single cell RNA sequencing data analysis demonstrated altered AAA metabolism in CSF and blood derived monocyte cell populations, while treatment of human peripheral blood mononuclear cells with AAA-derived metabotoxins resulted in increased production of tumor necrosis factor-α. We identify novel metabolic alterations in people with MS potentially contributing to disease pathophysiology.
BibTeX
@misc{fitzgerald2021multi,
  author = {Kathryn C. Fitzgerald and Matthew D. Smith and Elias S. Sotirchos and Michael D. Kornberg and Morgan Douglas and Bardia Nourbakhsh and Jennifer Graves and Ramandeep Rattan and Laila Poisson and Mirela Cerghet and Ellen M. Mowry and Emmanuelle Waubant and Shailendra Giri and Peter A. Calabresi and Pavan Bhargava},
  title = {{Multi-omic Evaluation of Metabolic Alterations in Multiple Sclerosis Identifies Shifts in Aromatic Amino Acid Metabolism}},
  year = {2021},
  doi = {10.1101/2020.12.30.20249031},
  howpublished = {medRxiv},
}
Figure